Fundraising Fox

Lantern Pharma

NASDAQ: LTRN

Dallas, US · Founded 2013 · Texas corporation · 32 employees on LinkedIn · 2 known investors

Lantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Lantern Pharma was founded in 2013 by Arunkumar Asaithambi.

AA
Arunkumar AsaithambiFounder
DR
David R. MargraveChief Financial Officer, Secretary
PSPanna Sharma
Panna SharmaChief Executive Officer, President
KG
Kishor G. BhatiaChief Scientific Officer
DK
David KeyserNamed on SEC filing
JF
John FucciNamed on SEC filing

Board

DJ
Donald Jeffrey KeyserChairman of the Board
LT
Lee T. SchalopBoard director
VC
Vijay ChandruBoard director
DS
David S. SilbersteinBoard director
MM
Maria MaccecchiniBoard director

Investors · 2

Green Park & Golf VenturesDallas · $500K – $2M
Health WildcattersDallas

Reported raises · per SEC filings

Form D private placements

$2.9M disclosed across 2 of 3 rounds · 2018–2026

▶Undisclosed amountofferedMay 2026 · 6 investors · Pharmaceuticals
Rule 506(b)
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpacebiospace.com · Aug 2026Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.comca.investing.com · Aug 2026
Officers, directors & promoters on the filing
  • Donald Jeffrey KeyserDirector
  • David R. MargraveExecutive Officer
  • Panna SharmaExecutive Officer, Director
  • Kishor G. BhatiaExecutive Officer
  • Lee T. SchalopDirector
  • Vijay ChandruDirector
  • David S. SilbersteinDirector
  • Maria MaccecchiniDirector
First sale
May 2026
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedMar 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David SilbersteinDirector
  • John FucciDirector
  • Arunkumar AsaithambiDirector
  • Panna SharmaExecutive Officer, Director
  • Donald KeyserDirector
Offering amount
$6.3M
Amount sold
$2.4M
Proceeds to insiders
$360K
First sale
Mar 2019
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$535KraisedJan 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David SilbersteinDirector
  • Panna SharmaExecutive Officer, Director
  • Arunkumar AsaithambiDirector
  • David KeyserDirector
  • John FucciDirector
Offering amount
$535K
Amount sold
$535K
First sale
Dec 2018
Incorporated
Corporation, Texas
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Lantern46 shared keywordsLantern operates a specialty care platform focused on complex, high-cost treatment such as surgery, cancer, and infusion therapy, connecting members to vetted providers with care team and nurse navigator support. It serves employers and health plans seeking to lower specialty care costs while maintaining quality outcomes.

Companies competing with Lantern Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpacebiospace.com · Aug 2026Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.comca.investing.com · Aug 2026Lantern Pharma’s bladder cancer trial cleared by EMA By Investing.cominvesting.com · Jul 2026Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding riskstocktitan.net · Jun 2026

Frequently asked questions

What does Lantern Pharma do?
Lantern Pharma is a pharmaceutical biotechnology company that applies machine learning and AI to oncology drug development, using data-driven hypothesis testing with in vitro and in vivo models. Its approach stratifies patient populations into responders and non-responders to de-risk clinical trials, develop companion diagnostics, and improve the likelihood of FDA approval at reduced cost.
Who founded Lantern Pharma?
Lantern Pharma was founded by Arunkumar Asaithambi in 2013.
Who are Lantern Pharma's investors?
Lantern Pharma's investors include Green Park & Golf Ventures, Health Wildcatters.
How much funding has Lantern Pharma raised?
Lantern Pharma has disclosed $2.9M raised across 2 of its 3 known rounds.
Where is Lantern Pharma headquartered?
Lantern Pharma is headquartered in Dallas, US.